Bernard Freudenthal

Bernard Freudenthal

Auto-generated profile, based on publicly available information

Bernard Freudenthal

Molecular Endocrinology Laboratory, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CHCynthia St. Hilaire
Cynthia St. Hilaire
SZShira G. Ziegler
Shira G. Ziegler
TMThomas C. Markello
Thomas C. Markello
ABAlfredo Brusco
Alfredo Brusco
CGCatherine Groden
Catherine Groden
MBManfred Boehm
Manfred Boehm
Arterial calcifications are associated with increased cardiovascular risk, but the genetic basis of this association is unclear. We performed clinical, radiographic, and genetic studies in three families with symptomatic arterial calcifications. Single-nucleotide-polymorphism analysis, targeted gene sequencing, quantitative polymerase-chain-reaction assays, Western blotting, enzyme measurements, transduction rescue experiments, and in vitro calcification assays were performed. We identified nine persons with calcifications of the lower-extremity arteries and hand and foot joint capsules: all five siblings in one family, three siblings in another, and one patient in a third family. Serum calcium, phosphate, and vitamin D levels were normal. Affected members of Family 1 shared a single 22.4-Mb region of homozygosity on chromosome 6 and had a homozygous nonsense mutation (c.662C→A, p.S221X) in NT5E, encoding CD73, which converts AMP to adenosine. Affected members of Family 2 had a homozygous missense mutation (c.1073G→A, p.C358Y) in NT5E. The proband of Family 3 was a compound heterozygote for c.662C→A and c.1609dupA (p.V537fsX7). All mutations found in the three families result in nonfunctional CD73. Cultured fibroblasts from affected members of Family 1 showed markedly reduced expression of NT5E messenger RNA, CD73 protein, and enzyme activity, as well as increased alkaline phosphatase levels and accumulated calcium phosphate crystals. Genetic rescue experiments normalized the CD73 and alkaline phosphatase activity in patients' cells, and adenosine treatment reduced the levels of alkaline phosphatase and calcification. We identified mutations in NT5E in members of three families with symptomatic arterial and joint calcifications. This gene encodes CD73, which converts AMP to adenosine, supporting a role for this metabolic pathway in inhibiting ectopic tissue calcification. (Funded by the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute of the National Institutes of Health.)

1 June 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
DMDimitrios-Anestis Moutzouris
Dimitrios-Anestis Moutzouris
LHLeal Herlitz
Leal Herlitz
GAGerald B. Appel
Gerald B. Appel
GMGlen S. Markowitz
Glen S. Markowitz
BFBernard Freudenthal
Bernard Freudenthal
VDVivette D. D'Agati
Vivette D. D'Agati
Background and objectives: Data regarding renal biopsy in the very elderly (≥age 80 yr) are extremely limited. The aim of this study was to examine the causes of renal disease and their clinical presentations in very elderly patients who underwent native renal biopsy. Design, setting, participants, & measurements: All native renal biopsies (n = 235 including 106 men, 129 women) performed in patients aged ≥80 yr over a 3.67-yr period were retrospectively identified. Results were compared with a control group of 264 patients aged 60 to 61 who were biopsied over the same period. Results: The indications for biopsy were acute kidney injury (AKI) in 46.4%, chronic-progressive kidney injury in 23.8%, nephrotic syndrome (NS) in 13.2%, NS with AKI in 9.4%, and isolated proteinuria in 5.5%. Pauci-immune GN was the most frequent diagnosis (19%), followed by focal segmental glomerulosclerosis secondary to hypertension (7.6%), hypertensive nephrosclerosis (7.1%), IgA nephropathy (7.1%) and membranous nephropathy (7.1%). Comparison with the control group showed pauci-immune GN to be more frequent (P < 0.001) and diabetic glomerulosclerosis (P < 0.001) and membranous nephropathy (P < 0.05) less frequent in the very elderly. Diagnostic information had the potential to modify treatment in 67% of biopsies from the very elderly, particularly in those with AKI or NS. Conclusions: Renal biopsy in very elderly patients is a valuable diagnostic tool that should be offered in clinical settings with maximal potential benefit. Advanced age per se should no longer be considered a contraindication to renal biopsy.

30 March 2011 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
DTDorothy Thompson
Dorothy Thompson
SFSally Feather
Sally Feather
HSHoria C. Stanescu
Horia C. Stanescu
BFBernard Freudenthal
Bernard Freudenthal
AZAnselm A. Zdebik
Anselm A. Zdebik
DBDetlef Bockenhauer
Detlef Bockenhauer
Non‐technical summary  Light stimulates ion flow through the retina. This generates a potential change at the cornea which is recorded as an electroretinogram (ERG). Our understanding of the role of potassium ions in generating the ERG is based on animal models. The KCJN10 gene constitutes Kir4.1, the principle potassium channel expressed on the retinal Muller cell. We have been able to study the impact of this potassium channel on the human retina for the first time by recording the ERGs of patients with EAST syndrome who have known mutations of KCJN10. Our data show a reduction in the amplitude of the photopic negative response of the light‐adapted ERG and a decrease in the sensitivity of the dark‐adapted ERG. These data increase our understanding of how the ERG is generated and why these ERG parameters may be affected in disease.

18 August 2011 in Nephron Physiology
Verified
Journal Article
Closed access
BFBernard Freudenthal
Bernard Freudenthal
DKDuvaraka Kulaveerasingam
Duvaraka Kulaveerasingam
LLLokesh Lingappa
Lokesh Lingappa
MSMehul A. Shah
Mehul A. Shah
LBLouise Brueton
Louise Brueton
AZAnselm A. Zdebik
Anselm A. Zdebik
Background/Aims: Mutations in the inwardly-rectifying K+ channel KCNJ10/Kir4.1 cause an autosomal recessive disorder characterized by epilepsy, ataxia, sensorineural deafness and tubulopathy (EAST syndrome). KCNJ10 is expressed in the kidney distal convoluted tubule, cochlear stria vascularis and brain glial cells. Patients clinically diagnosed with EAST syndrome were genotyped to identify and study mutations in KCNJ10. Methods: Patient DNA was sequenced and new mutations identified. Mutant and wild-type KCNJ10 constructs were cloned and heterologously expressed in Xenopus oocytes. Whole-cell K+ currents were measured by two-electrode voltage clamping. Results: Three new mutations in KCNJ10 (p.R65C, p.F75L and p.V259fs259X) were identified, and mutation p.R297C, previously only seen in a compound heterozygous patient, was found in a homozygous state. Wild-type human KCNJ10-expressing oocytes showed strongly inwardly-rectified currents, which by comparison were significantly reduced in all the mutants (p < 0.001). Specific inhibition of KCNJ10 currents by Ba2+ demonstrated residual function in all mutant channels (p < 0.05) but V259X. Conclusion: This study confirms that EAST syndrome can be caused by many different mutations in KCNJ10 that significantly reduce K+ conductance. EAST syndrome should be considered in any patient with a renal Gitelman-like phenotype with additional neurological signs and symptoms like ataxia, epilepsy or sensorineural deafness.

31 July 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DCDavid Church
David Church
LCLuís Cardoso
Luís Cardoso
RKRichard G Kay
Richard G Kay
CWClaire L Williams
Claire L Williams
BFBernard Freudenthal
Bernard Freudenthal
RSRobert K Semple
Robert K Semple
Context: Insulin autoimmune syndrome (IAS), spontaneous hyperinsulinemic hypoglycemia due to insulin-binding autoantibodies, may be difficult to distinguish from tumoral or other forms of hyperinsulinemic hypoglycemia, including surreptitious insulin administration. No standardized treatment regimen exists.Objectives: To evaluate an analytic approach to IAS and responses to different treatments.Design and Setting: Observational study in the UK Severe Insulin Resistance Service.Patients: Six patients with hyperinsulinemic hypoglycemia and detectable circulating anti–insulin antibody (IA).Main Outcome Measures: Glycemia, plasma insulin, and C-peptide concentrations by immunoassay or mass spectrometry (MS). Immunoreactive insulin was determined in the context of polyethylene glycol (PEG) precipitation and gel filtration chromatography (GFC). IA quantification using ELISA and RIA, and IA were further characterized using radioligand binding studies.Results: All patients were diagnosed with IAS (five IgG, one IgA) based on a high insulin/C-peptide ratio, low insulin recovery after PEG precipitation, and GFC evidence of antibody-bound insulin. Neither ELISA nor RIA result proved diagnostic for every case. MS provided a more robust quantification of insulin in the context of IA. One patient was managed conservatively, four were treated with diazoxide without sustained benefit, and four were treated with immunosuppression with highly variable responses. IA affinity did not appear to influence presentation or prognosis.Conclusions: IAS should be considered in patients with hyperinsulinemic hypoglycemia and a high insulin/C-peptide ratio. Low insulin recovery on PEG precipitation supports the presence of insulin-binding antibodies, with GFC providing definitive confirmation. Immunomodulatory therapy should be customized according to individual needs and clinical response.

1 October 2016 in Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
BFBernard Freudenthal
Bernard Freudenthal
JLJohn Logan
John Logan
PCPeter I Croucher
Peter I Croucher
GWGraham R Williams
Graham R Williams
JBJ H Duncan Bassett
J H Duncan Bassett
The genetic determinants of osteoporosis remain poorly understood, and there is a large unmet need for new treatments in our ageing society. Thus, new approaches for gene discovery in skeletal disease are required to complement the current genome-wide association studies in human populations. The International Knockout Mouse Consortium (IKMC) and the International Mouse Phenotyping Consortium (IMPC) provide such an opportunity. The IKMC generates knockout mice representing each of the known protein-coding genes in C57BL/6 mice and, as part of the IMPC initiative, the Origins of Bone and Cartilage Disease project identifies mutants with significant outlier skeletal phenotypes. This initiative will add value to data from large human cohorts and provide a new understanding of bone and cartilage pathophysiology, ultimately leading to the identification of novel drug targets for the treatment of skeletal disease.